PMHS (Polomar Health Services) Research & Development: $0.00 Mil (TTM As of Mar. 2026)


PMHS Polomar Health Services Inc PMHS
33 GF Score
Price $0.12
GF Value $12.34
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Polomar Health Services Research & Development?

Polomar Health Services PMHS -17.34% 33 Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus rates PMHS with a GF Score™ of 33/100 and a GF Value™ of $12.34 (Possible Value Trap). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Polomar Health Services's Research & Development for the three months ended in Mar. 2026 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Polomar Health Services  (OTCPK:PMHS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Polomar Health Services Research & Development Related Terms

Polomar Health Services Research & Development Historical Data

* Premium members only.

The historical data trend for Polomar Health Services's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polomar Health Services Research & Development Chart

Polomar Health Services Annual Data
Trend Dec07 Dec08 Dec09 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Polomar Health Services Quarterly Data
Dec09 Mar10 Jun10 Sep10 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PMHS
33GF Score
Polomar Health Services Inc PMHS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polomar Health Services Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
Polomar Health Services (PMHS) has a Research & Development of $0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Polomar Health Services and its competitors.
Is Polomar Health Services' Research & Development too high?
Polomar Health Services' current Research & Development is $0.00 Mil. Overall, Polomar Health Services has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Polomar Health Services' Research & Development compare to RDGT and DHTI?
Polomar Health Services' Research & Development of $0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Polomar Health Services and its competitors. Polomar Health Services's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polomar Health Services stock overvalued right now?
Based on GuruFocus' analysis, Polomar Health Services (PMHS) is currently considered Possible Value Trap. The stock's GF Value™ is $12.34, compared to a current price of $0.12 — trading 99% below its estimated fair value. The current Research & Development is $0.00 Mil. Polomar Health Services' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Polomar Health Services (PMHS), the current Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Polomar Health Services (PMHS) Overvalued in 2026?

Based on GuruFocus' analysis, Polomar Health Services stock appears to be undervalued. The current stock price of $0.12 is trading 99% below its estimated GF Value™ of $12.34. GuruFocus considers Polomar Health Services to be Possible Value Trap.

Key valuation signals for PMHS:

  • Research & Development: $0.00 Mil
  • GF Value™: $12.34 vs. price of $0.12 (99% below fair value)
  • GF Score™: 33/100 with 3 warning signs

No single metric tells the full story. See the PMHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Polomar Health Services Business Description

Address 32866 US Highway, 19 N, Los Angeles, FL, USA, 34684
Polomar Health Services Inc is a U.S.-based healthcare company specializing in retail compounding pharmacy services and prescription fulfillment for telehealth platforms. It is also licensed as a Special Sterile Compounding Pharmacy, permit #PH35277, which authorizes the licensed entity to dispense injectable and other sterile compounds (eye drops, infused therapeutics) upon receipt of a valid prescription. The firm is presently licensed and authorized to fulfill and deliver compounded prescribed medications in 28 states.
33GF Score

Get the complete analysis for PMHS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price
$12.34
GF Value